Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Company Deals

Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma

Fineline Cube Jul 16, 2026
Company Drug

Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy

Fineline Cube Jul 16, 2026
Company Drug

IMEIK Technology Receives NMPA Approval for Recombinant Human Hyaluronidase Clinical Study

Fineline Cube Dec 11, 2024

China-based IMEIK Technology Development Co., Ltd (SHE: 300896) has announced receiving approval from the National...

Company Drug

Patronus Biotech’s RSV Vaccine LYB005 Receives NMPA Approval for Clinical Study

Fineline Cube Dec 11, 2024

Guangzhou Patronus Biotech Co., Ltd., a vaccine start-up specializing in respiratory and infectious diseases, has...

Company Drug

Shanghai Pharmaceuticals’ SRD4610 Receives FDA Orphan Drug Designation for ALS Treatment

Fineline Cube Dec 11, 2024

China’s Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced that the US Food and...

Company Drug

Sperogenix Therapeutics’ Agamree Receives NMPA Approval for Duchenne Muscular Dystrophy Treatment

Fineline Cube Dec 11, 2024

China-based rare disease specialist Sperogenix Therapeutics Limited has announced receiving marketing approval from the National...

Policy / Regulatory

Beijing Expands Medical Insurance Sharing to Near Relatives with New Policy

Fineline Cube Dec 11, 2024

The Beijing Municipal Medical Insurance Bureau has released a notification that significantly expands the scope...

Company Drug

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for SHR-4394 and HRS-3802 Clinical Trials

Fineline Cube Dec 11, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...

Company Drug

Merck’s PD-1 Inhibitor Keytruda Approved by NMPA for Cervical Cancer Treatment in China

Fineline Cube Dec 11, 2024

US-based Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK) has announced receiving marketing approval from...

Company Drug

MSD’s Noxafil Receives NMPA Approval for Pediatric Use in Antifungal Treatment

Fineline Cube Dec 11, 2024

US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced that China’s National Medical...

Company Drug

NMPA Approves Zynlonta for Relapsed or Refractory Large B-Cell Lymphoma Treatment

Fineline Cube Dec 11, 2024

The website of China’s National Medical Products Administration (NMPA) has indicated that the marketing filing...

Company Drug

Wuhan YZY Biopharma’s M701 Shows Promise in Phase II Study for Malignant Pleural Effusion at ESMO ASIA 2024

Fineline Cube Dec 11, 2024

China-based Wuhan YZY Biopharma Co., Ltd (HKG: 2496) has announced the presentation of results from...

Company Deals

Porton Pharma Solutions and OD Kingsley Life Sciences Form Partnership for Bio Conjugated Drug Development

Fineline Cube Dec 11, 2024

China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions (SHE: 300363) has announced a...

Company Medical Device

Stereotaxis and MicroPort EP Receive NMPA Approval for Magbot Magnetic Navigation Ablation Catheter

Fineline Cube Dec 10, 2024

US-based Stereotaxis, Inc. (NYSEAMERICAN: STXS) and its Chinese partner Shanghai MicroPort EP Medtech Co., Ltd....

Company Drug

Immunofoco’s IMC002 Earns FDA Fast-Track Designation for CLDN 18.2-Positive Gastric Cancer

Fineline Cube Dec 10, 2024

Immunofoco, a leading developer in tumor immunotherapy based in Suzhou, has announced that it has...

Company Drug

InnoVec Biotherapeutics’ IVB102 Receives FDA IND Approval for X-Linked Retinoschisis Treatment

Fineline Cube Dec 10, 2024

Beijing-based gene therapy specialist InnoVec Biotherapeutics Inc. has announced receiving Investigational New Drug (IND) approval...

Company Deals

Nona Biosciences Partners with Kodiak Sciences to Discover Multi-Target Ophthalmic Antibodies

Fineline Cube Dec 10, 2024

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has joined forces with...

Company Drug

Eisai’s Urece (Dotinurad) Approved by China’s NMPA for Gout Treatment with Hyperuricemia

Fineline Cube Dec 10, 2024

Eisai’s (TYO: 4523) China unit has announced that it has received marketing approval from the...

Company Drug

Daiichi Sankyo and AstraZeneca’s Datopotamab Deruxtecan Earns FDA Breakthrough Therapy Designation

Fineline Cube Dec 10, 2024

Partners Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have jointly announced that their...

Company Deals

Shanghai Pharmaceuticals and Sichuan Kelun-Biotech Partner to Expand Sacituzumab Tirumotecan Market Access

Fineline Cube Dec 10, 2024

Shanghai Pharmaceuticals (SHA: 601607; SPH) has entered into a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical...

Company Drug

China Medical System’s Methylthioninium Tablets Receive First Prescriptions for Colonoscopy Use

Fineline Cube Dec 10, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that the first prescriptions have been...

Company Drug

Dizal Pharmaceutical Unveils Promising Data on DZD8586 for B-NHL at ASH Annual Meeting

Fineline Cube Dec 10, 2024

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has presented new data from a pooled safety...

Posts pagination

1 … 278 279 280 … 695

Recent updates

  • Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma
  • Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy
  • Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity
  • Fosun Pharma Secures NMPA Approval for FXR0906, Liver-Targeted siRNA Therapy for Hypertriglyceridemia
  • China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma

Company Drug

Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy

Company Drug

Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity

Company Drug

Fosun Pharma Secures NMPA Approval for FXR0906, Liver-Targeted siRNA Therapy for Hypertriglyceridemia

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.